Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro, I-53100 Siena, Italy; European Research Centre for Drug Discovery and Development (NatSynDrugs), I-53100 Siena, Italy.
Eur J Med Chem. 2013 Sep;67:344-51. doi: 10.1016/j.ejmech.2013.06.048. Epub 2013 Jul 1.
The development of a novel approach for the prediction of antiestrogenic activity is described, bringing up to date a previous pharmacophore study. Software Phase has been used to derive a 3D-QSAR model based, as alignment rule, on a pharmacophore built on three compounds highly active against MCF-7 cell line. Five features comprised the pharmacophore: two hydrogen-bond acceptors, one hydrogen-bond donor, and two aromatic rings. The sequential 3D-QSAR yielded a test set q(2) equal to 0.73 and proved to be predictive with respect to an external test set of 21 compounds (r(2) = 0.69). The model was used to detect new MCF-7 inhibitors through 3D-database searching and identified fourteen compounds that were subsequently tested in vitro against the MCF-7 human breast adenocarcinoma cell line. Eleven out of the fourteen compounds exhibited inhibitory activity with IC50 values ranging between 30 and 186 μM. The results of the study confirmed the fundamental validity of the chosen approach as a hit discovery tool.
本文描述了一种新的抗雌激素活性预测方法的开发,该方法对以前的药效团研究进行了更新。Phase 软件被用于基于三个对 MCF-7 细胞系高度有效的化合物构建的药效团,推导出一个 3D-QSAR 模型。该药效团包括两个氢键受体、一个氢键供体和两个芳环。顺序 3D-QSAR 得到了一个测试集 q(2)等于 0.73,并证明对于一个包含 21 个化合物的外部测试集具有预测性(r(2) = 0.69)。该模型用于通过 3D 数据库搜索来检测新的 MCF-7 抑制剂,并鉴定出 14 种随后在体外对 MCF-7 人乳腺癌腺癌细胞系进行测试的化合物。14 种化合物中有 11 种表现出抑制活性,IC50 值在 30 至 186 μM 之间。该研究结果证实了所选方法作为发现命中物的工具的基本有效性。